Galapagos Competitors

Galapagos (NASDAQ:GLPG) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Profitability

This table compares Galapagos and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Galapagos and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Galapagos. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Galapagos has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Galapagos and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Galapagos presently has a consensus price target of $180.1538, indicating a potential upside of 43.84%. Alexion Pharmaceuticals has a consensus price target of $145.25, indicating a potential upside of 18.47%. Given Galapagos' higher possible upside, research analysts clearly believe Galapagos is more favorable than Alexion Pharmaceuticals.

Institutional and Insider Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 84.2% of Alexion Pharmaceuticals shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Galapagos on 13 of the 15 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Galapagos and BeiGene's revenue, earnings per share and valuation.

Galapagos has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galapagos and BeiGene's net margins, return on equity and return on assets.

Institutional & Insider Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 52.6% of BeiGene shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Galapagos has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Galapagos and BeiGene, as provided by MarketBeat.com.

Galapagos presently has a consensus price target of $180.1538, suggesting a potential upside of 43.84%. BeiGene has a consensus price target of $237.7875, suggesting a potential downside of 13.15%. Given Galapagos' higher possible upside, equities analysts clearly believe Galapagos is more favorable than BeiGene.

Summary

Galapagos beats BeiGene on 7 of the 13 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Galapagos (NASDAQ:GLPG) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional and Insider Ownership

36.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 11.6% of Galapagos shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by company insiders. Comparatively, 2.9% of Galapagos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Royalty Pharma and Galapagos, as reported by MarketBeat.com.

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 29.04%. Galapagos has a consensus target price of $180.1538, suggesting a potential upside of 43.84%. Given Galapagos' higher possible upside, analysts clearly believe Galapagos is more favorable than Royalty Pharma.

Valuation & Earnings

This table compares Royalty Pharma and Galapagos' top-line revenue, earnings per share (EPS) and valuation.

Galapagos has higher revenue and earnings than Royalty Pharma.

Profitability

This table compares Royalty Pharma and Galapagos' net margins, return on equity and return on assets.

Summary

Galapagos beats Royalty Pharma on 6 of the 8 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Risk & Volatility

Galapagos has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Institutional and Insider Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 5.8% of Genmab A/S shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Galapagos and Genmab A/S, as reported by MarketBeat.com.

Galapagos presently has a consensus price target of $180.1538, suggesting a potential upside of 43.84%. Genmab A/S has a consensus price target of $38.8571, suggesting a potential upside of 7.82%. Given Galapagos' higher probable upside, analysts plainly believe Galapagos is more favorable than Genmab A/S.

Profitability

This table compares Galapagos and Genmab A/S's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Galapagos and Genmab A/S's top-line revenue, earnings per share and valuation.

Genmab A/S has lower revenue, but higher earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats Galapagos on 9 of the 14 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Catalent (NYSE:CTLT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Galapagos and Catalent, as provided by MarketBeat.

Galapagos currently has a consensus target price of $180.1538, indicating a potential upside of 43.84%. Catalent has a consensus target price of $105.50, indicating a potential upside of 5.71%. Given Galapagos' higher possible upside, equities analysts plainly believe Galapagos is more favorable than Catalent.

Insider & Institutional Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 91.0% of Catalent shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Galapagos and Catalent's gross revenue, earnings per share and valuation.

Catalent has higher revenue and earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Galapagos has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Galapagos and Catalent's net margins, return on equity and return on assets.

Summary

Catalent beats Galapagos on 10 of the 14 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Insider and Institutional Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 89.2% of Horizon Therapeutics Public shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Galapagos and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Galapagos and Horizon Therapeutics Public, as reported by MarketBeat.

Galapagos presently has a consensus price target of $180.1538, indicating a potential upside of 43.84%. Horizon Therapeutics Public has a consensus price target of $81.1667, indicating a potential upside of 15.87%. Given Galapagos' higher probable upside, analysts clearly believe Galapagos is more favorable than Horizon Therapeutics Public.

Volatility and Risk

Galapagos has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Valuation & Earnings

This table compares Galapagos and Horizon Therapeutics Public's revenue, earnings per share and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats Galapagos on 12 of the 14 factors compared between the two stocks.